A Review of Emerging ARNI Data in HFrEF

Published: 27 November 2019

  • Views:

    Views Icon 248
  • Likes:

    Heart Icon 7

Overview

Full programme

  • Views:

    Views Icon 248
  • Likes:

    Heart Icon 7
Part 5

of 8

Commentary on PROVE-HF and EVALUATE

Scott Solomon, Andrew JS Coats

Overview

Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.

Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.

Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.

This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.
 

EBAC Accreditation

This video series was funded by an unrestricted educational grant from Novartis.

Educational Objectives

  • Review updated data of ARNI therapy for HFrEF present at the ESC 2019
  • Understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases)
  • Interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data
  • Apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized patients.

More from this programme

Faculty biographies